Impact Biomedical (IBO) Non-Current Debt (2023 - 2025)
Impact Biomedical's (IBO) quarterly Non-Current Debt came in at $22.9 million in Q3 2025, up 187.05% YoY from $8.0 million in Q3 2024, and up 2.37% on a QoQ basis from $22.4 million in Q2 2025.
Impact Biomedical (IBO) Non-Current Debt (2023 - 2025) Analysis & Trends
Impact Biomedical (IBO) has 3 years of Non-Current Debt data on file, last reported at $22.9 million in Q3 2025.
- Quarterly Non-Current Debt rose 187.05% year-over-year to $22.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $22.9 million (up 187.05% YoY) and the FY2024 annual result came in at $8.9 million, down 26.47% from the prior year.
- Non-Current Debt improved to $22.9 million in Q3 2025, from $22.4 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $22.9 million in Q3 2025 to a low of $8.0 million in Q3 2024.
- A 3-year average of $13.9 million and a median of $10.6 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt slipped 26.47% — and 2025, when it surged 187.05%.
- Tracing IBO's Non-Current Debt over 3 years: stood at $12.1 million in 2023, then fell by 26.47% to $8.9 million in 2024, then soared by 157.73% to $22.9 million in 2025.
- The last three Non-Current Debt figures came in at $22.9 million (Q3 2025), $22.4 million (Q2 2025), and $9.1 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 22.88 Mn |
| Jun 30, 2025 | 22.35 Mn |
| Mar 31, 2025 | 9.14 Mn |
| Dec 31, 2024 | 8.88 Mn |
| Sep 30, 2024 | 7.97 Mn |
| Dec 31, 2023 | 12.07 Mn |